News & Analysis as of

Startups › Biotechnology › Funding

Rothwell, Figg, Ernst & Manbeck, P.C.

Capsida Biotherapeutics Debuts with $140 Million of Capital for its AAV Gene Therapies

Rothwell, Figg, Ernst & Manbeck, P.C. on

Capsida Biotherapeutics Inc.—a  Thousand Oaks, CA-based emerging biotechnology company—recently emerged from stealth mode with $ 140 million in start-up capital. Capsida secured a $50 million Series A commitment from Versant...more

Lowenstein Sandler LLP

Funding Life Sciences: Where The Opportunities And Resources Are In 2021 And Beyond

Lowenstein Sandler LLP on

Early-stage and small to midsize private and public companies in the life sciences sector began 2020 on a high note. Funding, particularly in the biotechnology sector, was pouring into the industry. Even several months into...more

McDonnell Boehnen Hulbert & Berghoff LLP

Second Quarter Venture Funding Increases 20% from First Quarter

McDonnell Boehnen Hulbert & Berghoff LLP on

Earlier this year, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its MoneyTree Report on venture funding for the second quarter of...more

Mintz - Intellectual Property Viewpoints

Crowdfunding and IP in Health and Biotech Start-ups (Part 1): The Beginning

Mintz - Intellectual Property Viewpoints on

Crowd Funding ImageThis is the first in a 3-part series about the use of crowdfunding in health and biotech start-ups. We start with the story of a tech start-up which set records for funding through a Kickstarter campaign,...more

McDonnell Boehnen Hulbert & Berghoff LLP

Venture Funding Reaches Highest Level in More Than a Decade

McDonnell Boehnen Hulbert & Berghoff LLP on

Last month, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its MoneyTree Report on venture funding for 2014. The report, which is...more

Broker-Dealer Compliance + Regulation

The Return of Biotech IPOs

Broker-Dealer Compliance + Regulation on

Biotech IPO market activity has recently returned to levels not seen since before the financial crisis. This has been brought about in part by the accommodations afforded issuers under the Jumpstart Our Business Startup Act...more

6 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide